Comparative Pharmacology
Head-to-head clinical analysis: FETROJA versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FETROJA versus TAZIDIME.
FETROJA vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefiderocol is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, and is stable against a broad range of beta-lactamases, including carbapenemases, due to its ability to penetrate the outer membrane via the bacterial iron transport system.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1 gram intravenously over 3 hours every 8 hours in patients 18 years and older with creatinine clearance ≥ 60 mL/min.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours; prolonged in renal impairment (e.g., up to 5-6 hours in severe renal impairment), requiring dose adjustment
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal: approximately 65-70% of the dose excreted unchanged in urine; biliary/fecal: minimal (<1%)
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic